Seven Fleet Capital Management LP Acquires Shares of 379,082 Perspective Therapeutics, Inc. $CATX

Seven Fleet Capital Management LP bought a new position in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 379,082 shares of the company’s stock, valued at approximately $1,581,000.

A number of other institutional investors have also modified their holdings of CATX. Aigen Investment Management LP bought a new stake in shares of Perspective Therapeutics during the fourth quarter valued at approximately $28,000. Russell Investments Group Ltd. boosted its holdings in shares of Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after purchasing an additional 5,475 shares during the period. nVerses Capital LLC bought a new position in Perspective Therapeutics in the fourth quarter worth approximately $31,000. AXQ Capital LP grew its stake in Perspective Therapeutics by 24.2% in the fourth quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after purchasing an additional 2,481 shares in the last quarter. Finally, Engineers Gate Manager LP purchased a new position in Perspective Therapeutics during the 4th quarter worth $35,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $2.91 on Friday. The company’s 50 day moving average is $3.22 and its 200 day moving average is $3.90. Perspective Therapeutics, Inc. has a 52-week low of $1.96 and a 52-week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%.The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.16 million. Sell-side analysts expect that Perspective Therapeutics, Inc. will post -1.1 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CATX. BTIG Research reaffirmed a “buy” rating on shares of Perspective Therapeutics in a research report on Friday, July 24th. Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. Eight equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Perspective Therapeutics has an average rating of “Buy” and a consensus price target of $12.62.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.